No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls

Dlugosz, Aldona; Winckler, Björn; Lundin, E.; Zakikhany, Katherina; Sandström, Gunnar; Ye, Weimin; Engstrand, Lars; Lindberg, Greger

doi:10.1038/srep08508

Cited by 73 publications

(75 citation statements)

References 48 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4). The SusCD-like proteins associated to the GH3 and GH16 are part of the experimentally validated PUL 105 (BACWH2_4099-BACWH2_4104)35 of B. cellulosilyticus WH2 (Fig. 5A and Table S2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A fibrolytic potential in the human ileum mucosal microbiota revealed by functional metagenomic

Patrascu

Béguet-Crespel

Marinelli

et al. 2017

Sci Rep

View full text Add to dashboard Cite

The digestion of dietary fibers is a major function of the human intestinal microbiota. So far this function has been attributed to the microorganisms inhabiting the colon, and many studies have focused on this distal part of the gastrointestinal tract using easily accessible fecal material. However, microbial fermentations, supported by the presence of short-chain fatty acids, are suspected to occur in the upper small intestine, particularly in the ileum. Using a fosmid library from the human ileal mucosa, we screened 20,000 clones for their activities against carboxymethylcellulose and xylans chosen as models of the major plant cell wall (PCW) polysaccharides from dietary fibres. Eleven positive clones revealed a broad range of CAZyme encoding genes from Bacteroides and Clostridiales species, as well as Polysaccharide Utilization Loci (PULs). The functional glycoside hydrolase genes were identified, and oligosaccharide break-down products examined from different polysaccharides including mixed-linkage β-glucans. CAZymes and PULs were also examined for their prevalence in human gut microbiome. Several clusters of genes of low prevalence in fecal microbiome suggested they belong to unidentified strains rather specifically established upstream the colon, in the ileum. Thus, the ileal mucosa-associated microbiota encompasses the enzymatic potential for PCW polysaccharide degradation in the small intestine.

show abstract

“…4). The SusCD-like proteins associated to the GH3 and GH16 are part of the experimentally validated PUL 105 (BACWH2_4099-BACWH2_4104)35 of B. cellulosilyticus WH2 (Fig. 5A and Table S2).…”

Section: Resultsmentioning

confidence: 99%

“…Up to date, only two different strains, CRE21 and WH2, have been described from this species, isolated from the human gut microbiota3545. Even if frequent in human gut metagenomes4, B. cellulosilyticus has been poorly studied.…”

Section: Discussionmentioning

confidence: 99%

A fibrolytic potential in the human ileum mucosal microbiota revealed by functional metagenomic

Patrascu

Béguet-Crespel

Marinelli

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…To simulate a normal, healthy, small intestine microbiome, a consortium of 7 bacterial species were selected to represent a healthy ileal microbiota 19 , 20 (Table 1). All bacteria were acquired from the German Collection of Microorganisms and Cell cultures (DSMZ).…”

Section: Methodsmentioning

confidence: 99%

A bacteriophage cocktail targetingEscherichia colireducesE. coliin simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota

et al. 2018

View full text Add to dashboard Cite

Antibiotics offer an efficient means for managing diseases caused by bacterial pathogens. However, antibiotics are typically broad spectrum and they can indiscriminately kill beneficial microbes in body habitats such as the gut, deleteriously affecting the commensal gut microbiota. In addition, many bacteria have developed or are developing resistance to antibiotics, which complicates treatment and creates significant challenges in clinical medicine. Therefore, there is a real and urgent medical need to develop alternative antimicrobial approaches that will kill specific problem-causing bacteria without disturbing a normal, and often beneficial, gut microbiota. One such potential alternative approach is the use of lytic bacteriophages for managing bacterial infections, including those caused by multidrug-resistant pathogens. In the present study, we comparatively analysed the efficacy of a bacteriophage cocktail targeting Escherichia coli with that of a broad-spectrum antibiotic (ciprofloxacin) using an in vitro model of the small intestine. The parameters examined included (i) the impact on a specific, pre-chosen targeted E. coli strain, and (ii) the impact on a selected non-targeted bacterial population, which was chosen to represent a defined microbial consortium typical of a healthy small intestine. During these studies, we also examined stability of bacteriophages against various pH and bile concentrations commonly found in the intestinal tract of humans. The bacteriophage cocktail was slightly more stable in the simulated duodenum conditions compared to the simulated ileum (0.12 vs. 0.58 log decrease in phage titers, respectively). It was equally effective as ciprofloxacin in reducing E. coli in the simulated gut conditions (2–3 log reduction), but had much milder (none) impact on the commensal, non-targeted bacteria compared to the antibiotic.

show abstract

“…Moreover, the ratio of Firmicutes to Bacteroidetes in the stool of IBS-D patients was 3-fold higher than healthy volunteers. In contrary, in a Swedish study no difference in small intestinal microbiota between IBS patients and healthy subjects was evidenced [8].…”

Section: Intestinal Microfloramentioning

confidence: 92%

IBS Patient’s Guide

Zielińska

2016

Introduction to Gastrointestinal Diseases Vol. 1

View full text Add to dashboard Cite

In this chapter, we will discuss the role of intestinal microbiota, lifestyle and eating habits in IBS patients. Before pharmacological treatment patients should consider changing lifestyle and diet, as they may be potential triggers for IBS symptoms. We will indicate which daily products are proper and which should be avoided by IBS patients because of exacerbation of disease symptoms. We will shortly describe how to lead healthy life and what the impact of physical activity on IBS symptoms is. We will explain that control, but not treatment, is the key management concept in IBS patients. Finally, we will define psychological aspects of IBS development and how important is to maintain psychological homeostasis. The continuous control of the doctor and regular good contact between the doctor and the patient play an important role in the disease remission.

show abstract

No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls

Cited by 73 publications

References 48 publications

A fibrolytic potential in the human ileum mucosal microbiota revealed by functional metagenomic

A fibrolytic potential in the human ileum mucosal microbiota revealed by functional metagenomic

A bacteriophage cocktail targetingEscherichia colireducesE. coliin simulated gut conditions, while preserving a non-targeted representative commensal normal microbiota

IBS Patient’s Guide

Contact Info

Product

Resources

About